Matrix Metalloproteinase 13
"Matrix Metalloproteinase 13" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A secreted matrix metalloproteinase that plays a physiological role in the degradation of extracellular matrix found in skeletal tissues. It is synthesized as an inactive precursor that is activated by the proteolytic cleavage of its N-terminal propeptide.
| Descriptor ID |
D053509
|
| MeSH Number(s) |
D08.811.277.656.300.480.205.363 D08.811.277.656.300.480.525.700.550 D08.811.277.656.675.374.205.363 D08.811.277.656.675.374.525.700.550 D12.644.276.848.550 D12.776.467.836.550
|
| Concept/Terms |
Matrix Metalloproteinase 13- Matrix Metalloproteinase 13
- Metalloproteinase 13, Matrix
- Matrix Metalloproteinase-13
- Metalloproteinase-13, Matrix
- MMP13 Metalloproteinase
- Metalloproteinase, MMP13
- MMP-13 Metalloproteinase
- MMP 13 Metalloproteinase
- Metalloproteinase, MMP-13
- Collagenase-3
- Collagenase 3
|
Below are MeSH descriptors whose meaning is more general than "Matrix Metalloproteinase 13".
Below are MeSH descriptors whose meaning is more specific than "Matrix Metalloproteinase 13".
This graph shows the total number of publications written about "Matrix Metalloproteinase 13" by people in this website by year, and whether "Matrix Metalloproteinase 13" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 1 | 1 |
| 2007 | 2 | 1 | 3 |
| 2008 | 0 | 3 | 3 |
| 2009 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 2 | 2 |
| 2017 | 0 | 1 | 1 |
| 2019 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Matrix Metalloproteinase 13" by people in Profiles.
-
TGF-? type 2 receptor-mediated modulation of the IL-36 family can be therapeutically targeted in osteoarthritis. Sci Transl Med. 2019 05 08; 11(491).
-
Exploration of CRISPR/Cas9-based gene editing as therapy for osteoarthritis. Ann Rheum Dis. 2019 05; 78(5):676-682.
-
Deletion of Runx2 in Articular Chondrocytes Decelerates the Progression of DMM-Induced Osteoarthritis in Adult Mice. Sci Rep. 2017 05 24; 7(1):2371.
-
Environmental disruption of circadian rhythm predisposes mice to osteoarthritis-like changes in knee joint. J Cell Physiol. 2015 Sep; 230(9):2174-2183.
-
Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is increased in osteoarthritis and regulates chondrocyte catabolic and anabolic activities. Osteoarthritis Cartilage. 2015 Sep; 23(9):1523-31.
-
MicroRNA-146a reduces IL-1 dependent inflammatory responses in the intervertebral disc. Gene. 2015 Jan 25; 555(2):80-7.
-
The anti-inflammatory and matrix restorative mechanisms of platelet-rich plasma in osteoarthritis. Am J Sports Med. 2014 Jan; 42(1):35-41.
-
Hyaluronan injection in murine osteoarthritis prevents TGFbeta 1-induced synovial neovascularization and fibrosis and maintains articular cartilage integrity by a CD44-dependent mechanism. Arthritis Res Ther. 2012 Jun 21; 14(3):R151.
-
Co-culture of mechanically injured cartilage with joint capsule tissue alters chondrocyte expression patterns and increases ADAMTS5 production. Arch Biochem Biophys. 2009 Sep; 489(1-2):118-26.
-
The action of resveratrol, a phytoestrogen found in grapes, on the intervertebral disc. Spine (Phila Pa 1976). 2008 Nov 15; 33(24):2586-95.